Literature DB >> 21034217

Orexin receptors: pharmacology and therapeutic opportunities.

Thomas E Scammell1, Christopher J Winrow.   

Abstract

Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors. In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents. This has generated considerable interest in developing small-molecule orexin receptor antagonists as a novel therapy for the treatment of insomnia. Orexin antagonists, especially those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clinical results are encouraging: Several compounds are in Phase III trials. As the orexin system mainly promotes arousal, these new compounds will likely improve insomnia without incurring many of the side effects encountered with current medications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21034217      PMCID: PMC3058259          DOI: 10.1146/annurev-pharmtox-010510-100528

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  135 in total

1.  Abnormal sleep/wake dynamics in orexin knockout mice.

Authors:  Cecilia G Diniz Behn; Elizabeth B Klerman; Takatoshi Mochizuki; Shih-Chieh Lin; Thomas E Scammell
Journal:  Sleep       Date:  2010-03       Impact factor: 5.849

Review 2.  Biomedical application of orexin/hypocretin receptor ligands in neuroscience.

Authors:  Christoph Boss; Catherine Brisbare-Roch; Francois Jenck
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

3.  Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.

Authors:  David B Whitman; Christopher D Cox; Michael J Breslin; Karen M Brashear; John D Schreier; Michael J Bogusky; Rodney A Bednar; Wei Lemaire; Joseph G Bruno; George D Hartman; Duane R Reiss; C Meacham Harrell; Richard L Kraus; Yuxing Li; Susan L Garson; Scott M Doran; Thomayant Prueksaritanont; Chunze Li; Christopher J Winrow; Kenneth S Koblan; John J Renger; Paul J Coleman
Journal:  ChemMedChem       Date:  2009-07       Impact factor: 3.466

4.  Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.

Authors:  Paul J Coleman; John D Schreier; Georgia B McGaughey; Michael J Bogusky; Christopher D Cox; George D Hartman; Richard G Ball; C Meacham Harrell; Duane R Reiss; Thomayant Prueksaritanont; Christopher J Winrow; John J Renger
Journal:  Bioorg Med Chem Lett       Date:  2010-02-08       Impact factor: 2.823

5.  Psychological health in central hypersomnias: the French Harmony study.

Authors:  Y Dauvilliers; J Paquereau; H Bastuji; X Drouot; J-S Weil; V Viot-Blanc
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-11       Impact factor: 10.154

6.  Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding.

Authors:  Christopher D Cox; Georgia B McGaughey; Michael J Bogusky; David B Whitman; Richard G Ball; Christopher J Winrow; John J Renger; Paul J Coleman
Journal:  Bioorg Med Chem Lett       Date:  2009-04-14       Impact factor: 2.823

Review 7.  REM sleep behavior disorder and narcolepsy.

Authors:  Michel Billiard
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-08       Impact factor: 4.388

8.  Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.

Authors:  Christine Dugovic; Jonathan E Shelton; Leah E Aluisio; Ian C Fraser; Xiaohui Jiang; Steven W Sutton; Pascal Bonaventure; Sujin Yun; Xiaorong Li; Brian Lord; Curt A Dvorak; Nicholas I Carruthers; Timothy W Lovenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-04-10       Impact factor: 4.030

9.  Involvement of TRPC3 channels in calcium oscillations mediated by OX(1) orexin receptors.

Authors:  Hanna M Peltonen; Johanna M Magga; Genevieve Bart; Pauli M Turunen; Miia S H Antikainen; Jyrki P Kukkonen; Karl E Akerman
Journal:  Biochem Biophys Res Commun       Date:  2009-05-21       Impact factor: 3.575

10.  The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system.

Authors:  Rodrigo A España; Erik B Oleson; Jason L Locke; Bethany R Brookshire; David C S Roberts; Sara R Jones
Journal:  Eur J Neurosci       Date:  2009-12-23       Impact factor: 3.386

View more
  109 in total

1.  Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation.

Authors:  Tian-Rui Xu; Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-03-02       Impact factor: 5.157

Review 2.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

3.  Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice.

Authors:  Jonathan E Elliott; Samuel E De Luche; Madeline J Churchill; Cindy Moore; Akiva S Cohen; Charles K Meshul; Miranda M Lim
Journal:  Sleep       Date:  2018-03-01       Impact factor: 5.849

4.  Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.

Authors:  James R Shoblock; Natalie Welty; Leah Aluisio; Ian Fraser; S Timothy Motley; Kirsten Morton; James Palmer; Pascal Bonaventure; Nicholas I Carruthers; Timothy W Lovenberg; Jamin Boggs; Ruggero Galici
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

5.  Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.

Authors:  Ka Lai Yee; Jacqueline McCrea; Deborah Panebianco; Wen Liu; Nicole Lewis; Tamara Cabalu; Steven Ramael; Rebecca E Wrishko
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

6.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

Review 7.  Sleep neurobiology from a clinical perspective.

Authors:  Rodrigo A España; Thomas E Scammell
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

8.  Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

9.  Hedonic Eating: Sex Differences and Characterization of Orexin Activation and Signaling.

Authors:  Laura Buczek; Jennifer Migliaccio; Gorica D Petrovich
Journal:  Neuroscience       Date:  2020-04-10       Impact factor: 3.590

Review 10.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.